1
|
Liposits G, Arora SP, Battisti NML, Soto-Perez-de-Celis E, Loh KP, Williams GR. Second-line FOLFOX is not the standard of care for all patients with advanced biliary tract cancer-a commentary from the Young International Society of Geriatric Oncology. Ann Oncol 2023; 34:555-556. [PMID: 36813114 DOI: 10.1016/j.annonc.2023.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2022] [Revised: 01/12/2023] [Accepted: 02/09/2023] [Indexed: 02/23/2023] Open
Affiliation(s)
- G Liposits
- Department of Oncology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Academy of Geriatric Cancer Research (AgeCare), Odense, Denmark.
| | - S P Arora
- Division of Hematology/Oncology, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, USA. https://twitter.com/DrSukeshiArora
| | - N M L Battisti
- Department of Medicine, The Royal Marsden NHS Foundation Trust, Sutton, UK; Breast Cancer Research Division, The Institute of Cancer Research, Sutton, London, UK. https://twitter.com/nicolobattisti
| | - E Soto-Perez-de-Celis
- Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. https://twitter.com/EnriqueSoto8
| | - K P Loh
- Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, USA. https://twitter.com/MelissaLoh21
| | - G R Williams
- Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, USA. https://twitter.com/GrantWilliamsMD
| |
Collapse
|
2
|
van Halteren HK, Bennouna J, Brasiuniene B, Tomas AJC, Trinidad AMG, Indini A, Liposits G, Pellegrino B, Popovic L, Tan A, Vidra R, Strijbos M. Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data. ESMO Open 2023; 8:100773. [PMID: 36634532 PMCID: PMC9843205 DOI: 10.1016/j.esmoop.2022.100773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 12/05/2022] [Accepted: 12/09/2022] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND During the European Society for Medical Oncology (ESMO) Congress 2022, outcome data of a great number of clinical trials were presented. For the attending medical oncologist, it is important to structure these data in a way that facilitates a trade-off between treatment burden and benefit. MATERIALS AND METHODS To illustrate this, we carried out a narrative non-systematic review of 12 selected oral presentations with potential impact on future daily practice, focusing on trial methodology, possible study flaws, reported clinical benefit and implementability. RESULTS The selected presentations encompassed 10 phase III trials, 1 randomized phase II trial and 1 phase II trial. In 7 out of 12 trials, quality of life and/or patient-reported outcomes had been evaluated. None of the trials, which reported progression-free survival (PFS) data, provided information, which could exclude informative censoring bias. In none of the trials reporting overall survival (OS) data, potential flaws due to undesirable crossover and imbalance between study groups regarding post-progression treatments were addressed. For the 11 reviewed randomized trials, the ESMO-Magnitude of Clinical Benefit Scale (MCBS) grade achieved with the new intervention was calculated based on the presented data. The MCBS grade varied from 1 to 5. CONCLUSIONS Our review confirms the high-quality standard of current cancer research and the clinical relevance of the research questions answered. However, during presentation of PFS and/or OS data, factors known to affect PFS and OS analysis should be structurally addressed. In order to keep cancer care affordable and sustainable, it could be considered to include an ESMO-MCBS threshold in the drug appraisal process of regulatory authorities.
Collapse
Affiliation(s)
- H K van Halteren
- Department of Medical Oncology, Adrz Hospital, Goes, The Netherlands.
| | - J Bennouna
- Department of Medical Oncology, Hospital Foch, Suresnes, France
| | - B Brasiuniene
- Department of Medical Oncology, National Cancer Institute of Lithuania, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - A J Cunquero Tomas
- Department of Medical Oncology, General University Hospital of Valencia, Valencia, Spain; Medical Oncology Unit, General Hospital of Requena, Valencia, Spain
| | - A M Garcia Trinidad
- Section of Medical Oncology, Dagupan Doctors Villaflor Memorial Hospital, Dagupan City, The Philippines
| | - A Indini
- Unit of Medical Oncology, Department of Oncology, Ospedale di Circolo e Fondazione Macchi, ASST Settelaghi, Varese, Italy
| | - G Liposits
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - B Pellegrino
- Medical Oncology and Breast Unit, University Hospital of Parma, Parma; Department of Medical Oncology, University of Parma, Parma, Italy
| | - L Popovic
- Oncology Institute of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
| | - A Tan
- Department of Medical Oncology, Waikato Hospital, Hamilton, New Zealand
| | - R Vidra
- Department of Medical Oncology, Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor", Cluj-Napoca, Romania; UBBMed, Babes-Bolyai University, Cluj-Napoca, Romania
| | - M Strijbos
- Department of Medical Oncology, GZA Hospitals, Wilrijk, Belgium
| |
Collapse
|
3
|
Liposits G, Ryg J, Skuladottir H, Winther S, Möller S, Hofsli E, Shah CH, Poulsen Oestergaard L, Berglund A, Qvortrup C, Osterlund P, Glimelius B, Sorbye H, Pfeiffer P. 410P Prognostic value of baseline ECOG performance status, frailty phenotype, and geriatric screening tools (G8 and VES-13) in vulnerable older patients with metastatic colorectal cancer: The randomized NORDIC9-study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
4
|
Osterlund P, Kinos S, Pfeiffer P, Salminen T, Kwakman J, Frödin JE, Shah C, Sorbye H, Ristamäki R, Halonen P, Soveri L, Heervä E, Ålgars A, Bärlund M, Hagman H, McDermott R, O’Reilly M, Röckert R, Liposits G, Kallio R, Flygare P, Teske A, van Werkhoven E, Punt C, Glimelius B. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open 2022; 7:100427. [PMID: 35798468 PMCID: PMC9291631 DOI: 10.1016/j.esmoop.2022.100427] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 11/23/2021] [Accepted: 12/18/2021] [Indexed: 12/14/2022] Open
|
5
|
Liposits G, Eshoj H, Möller S, Winther S, Skuladottir H, Jesper R, Hofsli E, Poulsen L, Shah C, Berglund Å, Qvortrup C, Osterlund P, Glimelius B, Sorbye H, Pfeiffer P. SO-15 Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Liposits G, Lichtman S. Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer - Staging the aging. Gynecol Oncol Rep 2021; 35:100710. [PMID: 33553556 PMCID: PMC7846923 DOI: 10.1016/j.gore.2021.100710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Revised: 12/21/2020] [Accepted: 01/12/2021] [Indexed: 11/25/2022] Open
Abstract
•Older patients are still underrepresented in randomized controlled clinical trials.•Older patients receiving PARP-inhibitors tend to achieve shorter PFS, even those considered fit.•Older patients experience more side effects, than their younger counterparts.•Prospective "real-world" data is needed in unselected older women with ovarian cancer receiving PARP-inhibitors.
Collapse
Affiliation(s)
- G. Liposits
- Department of Oncology, Odense University Hospital, J.B. Winsløws Vej 4., 5000 Odense C, Denmark
- Department of Clinical Research, University of Southern Denmark, Odense, J.B. Winsløws Vej 19.3, 5000 Odense C, Denmark
- Academy of Geriatric Cancer Research (AgeCare), Odense, Denmark
| | - S.M. Lichtman
- Memorial Sloan Kettering Cancer Center, Commack, USA
| |
Collapse
|
7
|
Pfeiffer P, Glimelius B, Winther S, Qvortrup C, Yilmaz M, Berglund À, Vistisen K, Kersten C, Liposits G, Sorbye H. Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Kovacs A, Antal G, Glavak C, Hadjiev J, Liposits G, Vandulek C, Lakosi F, Colen R, Repa I. EP-1183 TREATMENT OF HEAD-NECK CANCER PATIENTS USING CONPAS TECHNIQUE. 2 YEARS FOLLOW UP RESULTS. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)71516-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Liposits G, Hadjiev J, Kovacs A, Lakosi F, Gugyeras D, Antal G, Glavak C, Repa I, Bogner P. 2048 Adjuvant radiotherapy of endometrial carcinoma – 6-field vs. 4-field acute toxicity. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70564-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Kovacs A, Lakosi F, Hadzsiev J, Antal G, Vandulek C, Liposits G, Bogner P. TREATMENT OF HEAD-NECK CANCER PATIENTS USING CONPAS TECHNIQUE IN THE DAILY PRACTICE-TECHNICAL AND SIDE EFFECT1ANALYSiS1. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(12)73271-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Kovacs A, Hadjiev J, Lakosi F, Antal G, Liposits G, Bogner P. 119P TUMOR MOVEMENTS DETECTED BY MULTI-SLICE CT-BASED IMAGE FUSION IN THE RADIOTHERAPY OF LUNG CANCER. Lung Cancer 2009. [DOI: 10.1016/s0169-5002(09)70242-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|